Weltoss T 281.25 Injection
Generic Name:
Ceftriaxone & Tazobactam Injection
Brand Name:
Weltoss T 281.25 Injection
Strength:
Ceftriaxone 250 mg + Tazobactam 31.25 mg
Category:
Antibiotic Injectable
Pack Type:
Dry Powder Injection
Product Overview
Weltoss T 281.25 Injection is a combination of Ceftriaxone and Tazobactam, formulated to provide enhanced antibacterial protection against a wide range of bacterial infections, including infections caused by resistant organisms. Tazobactam acts as a beta-lactamase inhibitor, improving the effectiveness of Ceftriaxone and helping overcome bacterial resistance.
This advanced injectable antibiotic is widely used in hospitals, nursing homes, emergency departments, and critical care units for effective infection management.
Key Benefits
✔ Broad-spectrum antibacterial coverage
✔ Enhanced activity against resistant bacteria
✔ Beta-lactamase inhibitor protection
✔ Effective in moderate to severe infections
✔ Rapid infection management
✔ Suitable for hospital and critical care use
✔ High physician acceptance
Therapeutic Uses
- Respiratory Tract Infections
- Bronchitis
- Pneumonia
- Urinary Tract Infections (UTI)
- Skin & Soft Tissue Infections
- ENT Infections
- Intra-Abdominal Infections
- Gynecological Infections
- Bone & Joint Infections
- Post-Operative Infections
Mechanism of Action
Ceftriaxone is a third-generation cephalosporin antibiotic that destroys bacteria by inhibiting cell wall synthesis.
Tazobactam inhibits beta-lactamase enzymes produced by resistant bacteria, thereby protecting Ceftriaxone and enhancing its antibacterial activity.
Together, they provide superior infection control and broader bacterial coverage.
Product Details
| Parameter | Details |
|---|---|
| Product Name | Weltoss T 281.25 Injection |
| Generic Name | Ceftriaxone & Tazobactam Injection |
| Strength | 250 mg + 31.25 mg |
| Dosage Form | Injection |
| Category | Antibiotic Injectable |
| Therapeutic Segment | Anti-Infective |
| Prescription | Rx Only |
| Pack Type | Dry Powder Injection |
Why Choose Weltoss T 281.25 Injection?
- Advanced antibiotic combination
- Effective against resistant bacterial strains
- WHO-GMP quality manufacturing
- Reliable therapeutic performance
- Trusted by healthcare professionals
- Strong demand in institutional healthcare markets
PCD Pharma Franchise Opportunity
Weltoss T 281.25 Injection is available for PCD Pharma Franchise through Novalab Critical Care.
Franchise Benefits
- Monopoly Rights
- Promotional Inputs
- Visual Aids & Marketing Materials
- Business Development Support
- Timely Product Supply
- Attractive Growth Opportunities
Third Party Manufacturing Services
Novalab Critical Care offers Third Party Manufacturing Services for Ceftriaxone & Tazobactam Injection under WHO-GMP certified manufacturing facilities with strict quality assurance and regulatory compliance.
